Suchergebnisse - "Paoletti, Xavier"

PubPharm (110)

1

Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies : A Pooled Analysis of Phase III Trials

enthalten in: JCO precision oncology | 2019

von Pons-Tostivint, E. | Latouche, A. | Vaflard, P. | +11

2

Sequential or combined designs for Phase I/II clinical trials? A simulation study

enthalten in: Clinical trials (London, England) | 2019

von Rossoni, C. | Bardet, A. | Geoerger, B. | +1

3

Cumulative Toxicity in Targeted Therapies : What to Expect at the Recommended Phase II Dose

enthalten in: Journal of the National Cancer Institute | 2019

von Altzerinakou, M. | Collette, L. | Paoletti, X.

4

An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error

enthalten in: Contemporary clinical trials communications | 2019

von Belhechmi, S. | Michiels, S. | Paoletti, X. | +1

5

Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity

enthalten in: Pharmacology & therapeutics | 2019

von Chamseddine, A. | Ducreux, M. | Armand, J. | +4

6

Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI : https://doi.org/10.1002/pst.1873

enthalten in: Pharmaceutical statistics | 2019

von Jaki, T. | Gordon, A. | Forster, P. | +13

CommentOn: Pharm Stat. 2018 Sep;17(5):593-606. - PMID 29984474

7

Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score

enthalten in: PloS one | 2019

von Simon, M. | Bosset, P. | Rouanne, M. | +6

8

Randomized dose-escalation designs for drug combination cancer trials with immunotherapy

enthalten in: Journal of biopharmaceutical statistics | 2019

von Mozgunov, P. | Jaki, T. | Paoletti, X.

9

Response to comments on Jaki et al., a proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17( 5): 593‐ 606, Sep/Oct 2018.

enthalten in: Pharmaceutical statistics | 2019

von Jaki, T. | Gordon, A. | Forster, P. | +13

10

Randomized dose-escalation designs for drug combination cancer trials with immunotherapy

enthalten in: Journal of biopharmaceutical statistics | 2019

von Mozgunov, P. | Jaki, T. | Paoletti, X.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]